Rallybio Corporation (RLYB) is a Biotechnology company in the Healthcare sector, currently trading at $8.28. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: RLYB trades at a trailing Price-to-Earnings (P/E) of -4.8 (S&P 500 average ~25).
Financials: revenue is $858,000, +34.9%/yr average growth. Net income is $9M (loss), growing at +31.6%/yr. Net profit margin is -1046.4% (negative). Gross margin is 89.3% (+9.9 pp trend).
Balance sheet: total debt is $176,000 against $58M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 14.5 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $62M.
Analyst outlook: 4 / 8 analysts rate RLYB as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 40/100 (Partial), Income 10/100 (Fail).
